Abstract
Cardiovascular complications are among the main reasons for the high morbidity and mortality in patients with type 2 diabetes, making the management of cardiovascular complications an integral component in the treatment of type 2 diabetes. Along the same line, the US Food and Drug Administration mandated all new diabetic drugs and therapies have a safe cardiovascular profile. Among various drugs available for the treatment against type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a class of newly developed anti-diabetic agents with properties of mitigating cardiovascular risk in patients with type 2 diabetes. Evidence from clinical trials has suggested that the SGLT2 inhibitors empagliflozin and canagliflozin are capable of reducing the overall risk of cardiovascular events and mortality in type 2 diabetic patients. In this mini-review, we will briefly discuss the various cardiovascular benefits of SGLT2 inhibitors, and the underlying mechanisms involved.
Keywords: SGLT2, GLP-1, DPP-4, type 2 diabetes, cardiovascular, clinical.
Current Drug Targets
Title:Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon
Volume: 19 Issue: 9
Author(s): Dylan Y. Ren and Yingmei Zhang*
Affiliation:
- School of Pharmacy, University of Wyoming College of Health Sciences, Laramie, WY 82071,United States
Keywords: SGLT2, GLP-1, DPP-4, type 2 diabetes, cardiovascular, clinical.
Abstract: Cardiovascular complications are among the main reasons for the high morbidity and mortality in patients with type 2 diabetes, making the management of cardiovascular complications an integral component in the treatment of type 2 diabetes. Along the same line, the US Food and Drug Administration mandated all new diabetic drugs and therapies have a safe cardiovascular profile. Among various drugs available for the treatment against type 2 diabetes, the sodium-glucose cotransporter 2 (SGLT2) inhibitors represent a class of newly developed anti-diabetic agents with properties of mitigating cardiovascular risk in patients with type 2 diabetes. Evidence from clinical trials has suggested that the SGLT2 inhibitors empagliflozin and canagliflozin are capable of reducing the overall risk of cardiovascular events and mortality in type 2 diabetic patients. In this mini-review, we will briefly discuss the various cardiovascular benefits of SGLT2 inhibitors, and the underlying mechanisms involved.
Export Options
About this article
Cite this article as:
Ren Y. Dylan and Zhang Yingmei *, Cardiovascular Benefit of SGLT2 Inhibitors in the Therapeutics of Diabetes Mellitus: A Close Look beyond the Horizon, Current Drug Targets 2018; 19 (9) . https://dx.doi.org/10.2174/1389450119666180531102227
DOI https://dx.doi.org/10.2174/1389450119666180531102227 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Oxidative Stress in the Hypothalamus: the Importance of Calcium Signaling and Mitochondrial ROS in Body Weight Regulation
Current Neuropharmacology Cardiovascular Disease: What's All the AGE/RAGE About?
Cardiovascular & Hematological Disorders-Drug Targets Immune Modulation by Plasmid DNA-mediated Cytokine Gene Transfer
Current Pharmaceutical Design Macrovascular Complications of Type 2 Diabetes Mellitus
Current Vascular Pharmacology Natural Products Modulating Autophagy Pathway Against the Pathogenesis of Diabetes Mellitus
Current Drug Targets Wnt1 Inducible Signaling Pathway Protein 1 (WISP1) Blocks Neurodegeneration through Phosphoinositide 3 Kinase/Akt1 and Apoptotic Mitochondrial Signaling Involving Bad, Bax, Bim, and Bcl-xL
Current Neurovascular Research Cyclin-Dependent Kinase 5 (Cdk5): A Potential Therapeutic Target for the Treatment of Neurodegenerative Diseases and Diabetes Mellitus
Mini-Reviews in Medicinal Chemistry Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes
Endocrine, Metabolic & Immune Disorders - Drug Targets Serotonin – Kynurenine Hypothesis of Depression: Historical Overview and Recent Developments
Current Drug Targets Aspirin and Other Non-Steroidal Anti-Inflammatory Drugs as Cyclooxygenase Inhibitors: State of the Art, Barriers and Perspectives
Current Computer-Aided Drug Design Hypertension and Childhood Obesity: A Whirling Tango. A Review of the Dance Steps
Current Hypertension Reviews Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology Endothelial Changes in Individuals with Prehypertension
Current Hypertension Reviews Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Drug Disposition in Pathophysiological Conditions
Current Drug Metabolism Subject Index to Volume 5
Current Drug Targets Non-Invasive Methods of Glucose Measurement: Current Status and Future Perspectives
Current Diabetes Reviews CRH Receptor Signalling: Potential Roles in Pathophysiology
Current Molecular Pharmacology Nutrient-Induced Insulin Resistance in Human Skeletal Muscle
Current Medicinal Chemistry Association of Neutrophil-Lymphocyte Ratio with Mild Cognitive Impairment in Elderly Chinese Adults: A Case-control Study
Current Alzheimer Research